Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease

Thomas J. Montine, Joseph Quinn, Kathleen S. Montine, Jeffrey Kaye, John C S Breitner

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Dementia from Alzheimer's disease (AD) represents a significant and growing public health burden and presents a clear therapeutic imperative. Key to success in this undertaking will be biomarkers for the objective assessment of disease progression and response to therapeutics. Oxidative damage is one facet of AD pathogenesis for which there are experimentally validated quantitative in vivo biomarkers, the F2-isoprostanes (IsoPs). While plasma- or urine-based assays are desirable, consistent and reproducible cross-sectional data for increased F2-IsoPs in AD and mild cognitive impairment have been obtained only for CSF. In addition, measurement of CSF F2-IsoPs can increase the accuracy of laboratory-based classification of geriatric dementias, and have been used to assess objectively the response to anti-oxidant interventions in AD.

Original languageEnglish (US)
Pages (from-to)359-367
Number of pages9
JournalJournal of Alzheimer's Disease
Volume8
Issue number4
StatePublished - 2005
Externally publishedYes

Fingerprint

F2-Isoprostanes
Alzheimer Disease
Biomarkers
Dementia
Oxidants
Geriatrics
Disease Progression
Public Health
Urine
Therapeutics

Keywords

  • Alzheimer's disease
  • Biomarkers
  • F2-isoprostanes
  • Oxidative stress

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology

Cite this

Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease. / Montine, Thomas J.; Quinn, Joseph; Montine, Kathleen S.; Kaye, Jeffrey; Breitner, John C S.

In: Journal of Alzheimer's Disease, Vol. 8, No. 4, 2005, p. 359-367.

Research output: Contribution to journalArticle

@article{f49ea4329c0848ed95a983c0a0f33f3f,
title = "Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease",
abstract = "Dementia from Alzheimer's disease (AD) represents a significant and growing public health burden and presents a clear therapeutic imperative. Key to success in this undertaking will be biomarkers for the objective assessment of disease progression and response to therapeutics. Oxidative damage is one facet of AD pathogenesis for which there are experimentally validated quantitative in vivo biomarkers, the F2-isoprostanes (IsoPs). While plasma- or urine-based assays are desirable, consistent and reproducible cross-sectional data for increased F2-IsoPs in AD and mild cognitive impairment have been obtained only for CSF. In addition, measurement of CSF F2-IsoPs can increase the accuracy of laboratory-based classification of geriatric dementias, and have been used to assess objectively the response to anti-oxidant interventions in AD.",
keywords = "Alzheimer's disease, Biomarkers, F2-isoprostanes, Oxidative stress",
author = "Montine, {Thomas J.} and Joseph Quinn and Montine, {Kathleen S.} and Jeffrey Kaye and Breitner, {John C S}",
year = "2005",
language = "English (US)",
volume = "8",
pages = "359--367",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "4",

}

TY - JOUR

T1 - Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease

AU - Montine, Thomas J.

AU - Quinn, Joseph

AU - Montine, Kathleen S.

AU - Kaye, Jeffrey

AU - Breitner, John C S

PY - 2005

Y1 - 2005

N2 - Dementia from Alzheimer's disease (AD) represents a significant and growing public health burden and presents a clear therapeutic imperative. Key to success in this undertaking will be biomarkers for the objective assessment of disease progression and response to therapeutics. Oxidative damage is one facet of AD pathogenesis for which there are experimentally validated quantitative in vivo biomarkers, the F2-isoprostanes (IsoPs). While plasma- or urine-based assays are desirable, consistent and reproducible cross-sectional data for increased F2-IsoPs in AD and mild cognitive impairment have been obtained only for CSF. In addition, measurement of CSF F2-IsoPs can increase the accuracy of laboratory-based classification of geriatric dementias, and have been used to assess objectively the response to anti-oxidant interventions in AD.

AB - Dementia from Alzheimer's disease (AD) represents a significant and growing public health burden and presents a clear therapeutic imperative. Key to success in this undertaking will be biomarkers for the objective assessment of disease progression and response to therapeutics. Oxidative damage is one facet of AD pathogenesis for which there are experimentally validated quantitative in vivo biomarkers, the F2-isoprostanes (IsoPs). While plasma- or urine-based assays are desirable, consistent and reproducible cross-sectional data for increased F2-IsoPs in AD and mild cognitive impairment have been obtained only for CSF. In addition, measurement of CSF F2-IsoPs can increase the accuracy of laboratory-based classification of geriatric dementias, and have been used to assess objectively the response to anti-oxidant interventions in AD.

KW - Alzheimer's disease

KW - Biomarkers

KW - F2-isoprostanes

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=33645084250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645084250&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 359

EP - 367

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 4

ER -